We aim to make Biopharmaceuticals more Affordable10 Jun 2016
Led by an experienced team of Genentech and Amgen veterans JHL Biotech aims to make biopharmaceuticals affordable and accessible to all patients through manufacturing innovation Several Asian companies have been increasing their focus on biosimilars, terming it a long term prospect. Although currently small and focused on few diseases, the biosimilars opportunity is all set to grow, thanks to the unprecedented patent cliff and rising healthcare costs. Biosimilars are an affordable option for Asia's growing healthcare needs and this has offered a clear potential for players in emerging Asian countries to set up operations and leverage this lucrative opportunity.
JHL TEAM POISED FOR SUCCESS 201510 Dec 2015
JHL TEAM POISED FOR SUCCESS 2015
JHL CEO Presents at the 4th Annual Biologics World Korea June 9, 201509 Jun 2015
Racho Jordanov, Co-founder, President, and CEO of JHL Biotech, presented at the 4th Annual Biologics World in Seoul, Korea on June 9, 2015
JHL Biotech Presents at 2015 Biopharma Development and Production Conference20 May 2015
JHL Biotech Presents at 2015 Biopharma Development and Production Conference May 20, 2015
JHL CEO Presents at International Therapeutic Antibody Summit17 Oct 2013
Racho Jordanov, Co-founder, President, and CEO of JHL Biotech, presented at the Second International Therapeutic Antibody Summit in Wuhan, China on October 17, 2013.